Pluri Inc. Other Cost of Operating Revenue
Pluri Inc. (PLUR) reported Other Cost of Operating Revenue of ILS 10.00 billion for the 12-month period ending 2025-06-30, per its 10-K filed 2025-09-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherCostOfOperatingRevenue · last filed 2025-09-17
- Pluri Inc. other cost of operating revenue for fiscal 2025 was 10.00B ILS, a 0.00% change from fiscal 2024.
- Pluri Inc. other cost of operating revenue for fiscal 2024 was 10.00B ILS, a 0.00% change from fiscal 2023.
- Pluri Inc. other cost of operating revenue for fiscal 2023 was 10.00B ILS.
ILS
| Period end | Other Cost of Operating Revenue 12 month |
|---|---|
| 2025-06-30 | 10.00B ILS 10-K · filed 2025-09-17 |
| 2024-06-30 | 10.00B ILS 10-K · filed 2024-09-18 |
| 2023-06-30 | 10.00B ILS 10-K · filed 2023-09-12 |
USD
| Period end | Other Cost of Operating Revenue 12 month |
|---|---|
| 2025-06-30 | $2.90B 10-K · filed 2025-09-17 |
| 2024-06-30 | $2.90B 10-K · filed 2024-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |